SCHEMBL3930652

SCHEMBL3930652

COC(=O)C(C)(C)NC(=O)c1ccc2ccccc2c1OC(C)COc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 12/20 0.55
LMNA P02545 1/20 0.41
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTT P42858 1/20 0.37
CASR P41180 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926633 0.92 CXCR2 (0.59) CXCR2LMNARAB9ACASRMTNR1A
SCHEMBL3925427 0.92 CXCR2 (0.59) CXCR2LMNARAB9ACASRMTNR1A
SCHEMBL3927655 0.92 CXCR2 (0.59) CXCR2LMNARAB9ACASRMTNR1A
SCHEMBL3923021 0.83 HDAC3 (0.53) CXCR2LMNARAB9AMEN1KMT2A
SCHEMBL3928479 0.81 CXCR2 (0.47) CXCR2LMNAHTTHDAC3HDAC4
SCHEMBL3927105 0.78 CXCR2 (0.55) CXCR2LMNARAB9AMEN1KMT2A
SCHEMBL3927704 0.78 CXCR2 (0.54) CXCR2LMNARAB9AMEN1KMT2A
SCHEMBL3933702 0.76 CXCR2 (0.64) CXCR2LMNAMEN1KMT2A
SCHEMBL485483 0.76 CXCR2 (0.53) CXCR2LMNARAB9AMEN1KMT2A
SCHEMBL3926130 0.76 CXCR2 (0.64) CXCR2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 US disclosed
US-20090227625-A1 CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2009-09-10 US disclosed
EP-2040688-A1 NEW CXCR2 INHIBITORS Sanofi-Aventis (FR) 2009-04-01 EP disclosed
WO-2008000409-A1 NEW CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227625-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 CXCR2 1/4885LMNA 4404/4885RAB9A 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.